Cargando…

The Correlations Between Plasma Fibrinogen With Amyloid-Beta and Tau Levels in Patients With Alzheimer’s Disease

Recent studies show that fibrinogen plays a role in the pathogenesis of Alzheimer’s disease (AD), which may be crucial to neurovascular damage and cognitive impairment. However, there are few clinical studies on the relationship between fibrinogen and AD. 59 (11)C-PiB-PET diagnosed AD patients and 7...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Dong-Yu, Sun, Hao-Lun, Sun, Pu-Yang, Jian, Jie-Ming, Li, Wei-Wei, Shen, Ying-Ying, Zeng, Fan, Wang, Yan-Jiang, Bu, Xian-Le
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859103/ https://www.ncbi.nlm.nih.gov/pubmed/33551734 http://dx.doi.org/10.3389/fnins.2020.625844

Ejemplares similares

The Correlations of Plasma and Cerebrospinal Fluid Amyloid-Beta Levels with Platelet Count in Patients with Alzheimer's Disease
por: Sun, Hao-Lun, et al.
Publicado: (2018)

Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer’s disease
por: Chen, Si-Han, et al.
Publicado: (2020)

Associations of plasma angiostatin and amyloid-β and tau levels in Alzheimer’s disease
por: Cheng, Yuan, et al.
Publicado: (2022)

The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
por: Yin, Xiaomin, et al.
Publicado: (2021)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition
por: Risacher, Shannon L., et al.
Publicado: (2019)

Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
por: Roda, Alejandro R., et al.
Publicado: (2022)

Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer’s disease dementia in Chinese individuals
por: Sun, Qingling, et al.
Publicado: (2022)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Neurobiological pathways to Alzheimer’s disease: Amyloid-beta, TAU protein or both?
por: de Paula, Vanessa de Jesus R., et al.
Publicado: (2009)

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
por: den Haan, Jurre, et al.
Publicado: (2018)

Non-linear Character of Plasma Amyloid Beta Over the Course of Cognitive Decline in Alzheimer’s Continuum
por: Pan, Feng-Feng, et al.
Publicado: (2022)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer’s disease
por: Xiang, Yang, et al.
Publicado: (2015)

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer’s disease
por: Lambracht-Washington, Doris, et al.
Publicado: (2013)

Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer’s Disease
por: Lee, Ni-Chung, et al.
Publicado: (2017)

Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease
por: Reddy, P. Hemachandra, et al.
Publicado: (2019)

Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease
por: Patow, Gustavo, et al.
Publicado: (2023)

Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer’s Disease
por: Mullins, Roger J., et al.
Publicado: (2017)

Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies
por: Lue, Lih-Fen, et al.
Publicado: (2017)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

JBPOS0101 regulates amyloid beta, tau, and glial cells in an Alzheimer’s disease model
por: Jeong, Jihoon, et al.
Publicado: (2020)

Distinct Molecular Signatures of Amyloid-Beta and Tau in Alzheimer’s Disease Associated with Down Syndrome
por: Ichimata, Shojiro, et al.
Publicado: (2023)

Electrochemical Immunosensors Developed for Amyloid-Beta and Tau Proteins, Leading Biomarkers of Alzheimer’s Disease
por: Sharma, Abhinav, et al.
Publicado: (2023)

Focal-type, but not Diffuse-type, Amyloid Beta Plaques are Correlated with Alzheimer’s Neuropathology, Cognitive Dysfunction, and Neuroinflammation in the Human Hippocampus
por: Liu, Fan, et al.
Publicado: (2022)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
por: Startin, Carla M., et al.
Publicado: (2019)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimer's Disease Treatment: Rethinking the Current Strategy
por: Mondragón-Rodríguez, Siddhartha, et al.
Publicado: (2012)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer’s disease
por: Burns, Lindsay H., et al.
Publicado: (2017)

Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers
por: Chen, Ting-Bin, et al.
Publicado: (2021)

Toxicities of amyloid-beta and tau protein are reciprocally enhanced in the Drosophila model
por: Sun, Zhen-Dong, et al.
Publicado: (2022)

Serum amyloid-beta levels are increased in patients with obstructive sleep apnea syndrome
por: Bu, Xian-Le, et al.
Publicado: (2015)

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
por: Doré, Vincent, et al.
Publicado: (2022)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Mechanical Dilution of Beta-amyloid Peptide and Phosphorylated Tau Protein in Alzheimer's Disease: Too Simple to be True?
por: Menéndez González, Manuel
Publicado: (2017)

Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of Alzheimer’s Disease
por: Pickett, Eleanor K., et al.
Publicado: (2019)

The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study
por: Ismail, Rola, et al.
Publicado: (2020)

Mass spectrometry analysis of tau and amyloid‐beta in iPSC‐derived models of Alzheimer’s disease and dementia
por: Arber, Charles, et al.
Publicado: (2021)

A small molecule transcription factor EB activator ameliorates beta‐amyloid precursor protein and Tau pathology in Alzheimer's disease models
por: Song, Ju‐Xian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_91f2mqkcq26pb4i1poc4gvj8g1